Monoclonal antibodies that inhibit activation and proliferation of lymphocytes. I. Expression of the antigen on monocytes and activated lymphocytes
- PMID: 3950410
Monoclonal antibodies that inhibit activation and proliferation of lymphocytes. I. Expression of the antigen on monocytes and activated lymphocytes
Abstract
It has been shown previously that HBJ127 and HBJ98 monoclonal antibodies raised against a human bladder cancer cell line, and B3 monoclonal antibody against a rat bladder cancer cell line recognized unique cell surface antigens abundant in proliferating cells of the corresponding species. Distribution of the antigens and kinetics of the appearance on human and rat lymphoid cells were examined by means of flow cytometry. Rat macrophages and human peripheral blood monocytes were stained strongly with the B3 and HBJ127 monoclonal antibodies, respectively. With regard to lymphocytes, the expression of the B3-defined antigen on rat lymphocytes was found to have a negative correlation with the maturation of the lymphocytes; the antigen was most abundant in bone marrow cells, less abundant in thymocytes, and least abundant in spleen, lymph node, and peripheral blood lymphocytes. Similarly, the HBJ127-defined antigen on human peripheral lymphocytes was negligible. On activation with Con A or alloantigens, however, both rat and human T lymphocytes did strongly express these antigens. Activation of human or rat B cells with lipopolysaccharide also resulted in the augmented expression of these antigens. Kinetics studies revealed that the antigen expression was readily manifested within 12 hr on activation of rat or human T cells with Con A, was augmented progressively with culture time, and reached a plateau within 36 hr. This somewhat earlier appearance of these antigens apparently preceded the manifestations of the IL 2 receptor (Tac antigen) and the augmented DNA synthesis. The B3-defined antigen on Con A-stimulated T cells was more rich on the lymphocytes in S and G2/M phases than those in G1 phase, and the expression was not significantly affected by the addition of hydroxyurea, but was moderately inhibited by the addition of sodium butylate. These results suggest that the appearance and expression of the B3-defined antigen and probably also those of the HBJ127/HBJ98-defined antigen are correlated with lymphocyte activation and subsequent progression through the cell cycle.
Similar articles
-
Monoclonal antibodies that inhibit activation and proliferation of lymphocytes. II. Requisite role of the monoclonal antibody-defined antigen systems in activation and proliferation of human and rat lymphocytes.J Immunol. 1986 Mar 15;136(6):2062-8. J Immunol. 1986. PMID: 2419421
-
Inhibition of tumor cell growth in vitro by murine monoclonal antibodies that recognize a proliferation-associated cell surface antigen system in rats and humans.Cancer Res. 1986 Mar;46(3):1478-84. Cancer Res. 1986. PMID: 2417704
-
Lymphocyte activation antigens. I. A monoclonal antibody, anti-Act I, defines a new late lymphocyte activation antigen.J Immunol. 1984 Oct;133(4):1857-62. J Immunol. 1984. PMID: 6088627
-
Rabbit leukocyte surface antigens defined by monoclonal antibodies.Eur J Immunol. 1983 Nov;13(11):919-28. doi: 10.1002/eji.1830131111. Eur J Immunol. 1983. PMID: 6605862
-
Antigen-specific cytometry.Arthritis Res. 1999;1(1):25-9. doi: 10.1186/ar7. Epub 1999 Oct 26. Arthritis Res. 1999. PMID: 11094410 Free PMC article. Review. No abstract available.
Cited by
-
Anti-tumor effect against human cancer xenografts by a fully human monoclonal antibody to a variant 8-epitope of CD44R1 expressed on cancer stem cells.PLoS One. 2012;7(1):e29728. doi: 10.1371/journal.pone.0029728. Epub 2012 Jan 17. PLoS One. 2012. PMID: 22272243 Free PMC article.
-
Changes in activation markers and cell membrane receptors on human peripheral blood T lymphocytes during cell cycle progression after PHA stimulation.Immunology. 1988 Jul;64(3):419-25. Immunology. 1988. PMID: 3261709 Free PMC article.
-
Anti-tumor effects of mAb against L-type amino acid transporter 1 (LAT1) bound to human and monkey LAT1 with dual avidity modes.Cancer Sci. 2019 Feb;110(2):674-685. doi: 10.1111/cas.13908. Epub 2019 Jan 4. Cancer Sci. 2019. PMID: 30548114 Free PMC article.
-
Oncogenic transformation of NIH/3T3 cells by the overexpression of L-type amino acid transporter 1, a promising anti-cancer target.Oncotarget. 2021 Jun 22;12(13):1256-1270. doi: 10.18632/oncotarget.27981. eCollection 2021 Jun 22. Oncotarget. 2021. PMID: 34194623 Free PMC article.
-
Antibody epitope peptides as potential inducers of IgG antibodies against CD98 oncoprotein.Cancer Sci. 2009 Jan;100(1):126-31. doi: 10.1111/j.1349-7006.2008.00998.x. Epub 2008 Oct 29. Cancer Sci. 2009. PMID: 19018757 Free PMC article.